课题基金 / 基金详情

Serine Protease Modulation of ErbB Receptors

Serine Protease Modulation of ErbB Receptors
ErbB 受体的丝氨酸蛋白酶调节
批准号:
8099942
负责人:
KARL X CHAI
金额:
$31.14万
依托单位国家:
美国
项目类别:
财政年份:
2011
资助国家:
美国
项目状态:
已结题
起止时间:
2011-04-01 至 2015-06-30

项目摘要

项目成果

KARL X CHAI的其他基金

相似基金

相关文献

中文摘要
翻译
描述(由申请人提供):Her2+/uPA+乳腺癌在临床上是最具侵袭性的,比Her2+/uPA-、Her2-/uPA+和Her2-/uPA-亚型更具侵袭性。Her2/neu/ErbB2受体酪氨酸激酶信号通过尿激酶型纤溶酶原激活物(uPA)和一个新的胞外膜丝氨酸蛋白酶网络通过胞外结构域/外结构域(ECD)脱落的蛋白水解调节被假设在Her2+/uPA+乳腺癌的侵袭行为和单克隆抗体或小分子酪氨酸激酶抑制剂药物抗Her2治疗的抗性中发挥机制作用。因此,在Her2+/uPA+乳腺癌中同时靶向Her2和uPA可能是治疗这些癌症的更有效策略;也可能是所有Her2阳性乳腺癌这个假设将在这个项目中进行检验。基于以下具体目标,我们将创建Her2+/uPA+乳腺癌的新型细胞系模型,并通过同时靶向Her2和uPA来测试一种新型治疗策略的有效性。我们还将研究几种与乳腺癌和许多其他癌症相关的细胞膜外丝氨酸蛋白酶的新功能作用。具体目标建立Her2+/uPA+人乳腺癌细胞系,评价其增强侵袭性。我们将通过在Her2扩增的SK-BR-3和BT-474细胞系中过表达uPA/uPAR或在uPA+但Her2阴性(未扩增)的MDA-MB-231细胞系中过表达Her2来建立Her2+/uPA+人乳腺癌细胞系;并在体外评估肿瘤在增殖、迁移、侵袭和不依赖锚定生长方面的侵袭性。具体目标2。联合赫赛汀、拉帕替尼和WX-UK1治疗Her2+/uPA+人乳腺癌细胞系,评价联合靶向Her2和uPA的有效性。通过我们的工程Her2+/uPA+模型细胞系,将解决以下临床相关问题:1)Her2+/uPA+乳腺癌是否对赫赛汀甚至拉帕替尼出现新耐药,以及选择性uPA抑制剂WX-UK1抑制uPA是否克服了耐药;2) Her2+/uPA+乳腺癌是否更积极地获得抗Her2治疗的耐药,以及WX-UK1抑制uPA是否延迟了耐药的获得。具体目标3。确定基质酶、前列腺素和uPA对Her2 ECD的特异性作用。我们将使用FT-293细胞系进行共转染实验,以确定uPA是否是Her2 ECD脱落酶,以及纤溶酶是否在Her2 ECD脱落中起作用;纯化蛋白酶裂解的Her2,用于定位裂解位点;并确定蛋白酶裂解的Her2是否对赫赛汀诱导的周转有反应。我们将使用SK-BR-3细胞系,通过使用特定抑制剂来确定乳腺癌细胞中与uPA诱导相关的Her2 ECD脱落是否也涉及或需要基质酶和前列腺蛋白酶。
英文摘要
DESCRIPTION (provided by applicant): The Her2+/uPA+ breast cancers are clinically the most aggressive, more so than the Her2+/uPA-, Her2-/uPA+, and Her2-/uPA- subtypes. Proteolytic modulation of Her2/neu/ErbB2 receptor tyrosine kinase signaling via extracellular domain/ectodomain (ECD) shedding by the urokinase-type plasminogen activator (uPA) and a novel network of extracellular membrane serine proteases is hypothesized to play a mechanistic role in the aggressive behaviors of the Her2+/uPA+ breast cancers and in resistance to anti-Her2 therapies using monoclonal antibody or small-molecule tyrosine kinase inhibitor drugs. Targeting Her2 and uPA simultaneously in Her2+/uPA+ breast cancers could therefore be a more effective strategy of treating these cancers; and potentially all Her2+ breast cancers. This hypothesis will be tested in this project. With the following specific aims, we will be creating novel cell-line models of Her2+/uPA+ breast cancer and testing the effectiveness of a novel treatment strategy by targeting Her2 and uPA simultaneously. We will also be investigating novel functional roles of several extracellular membrane serine proteases associated with breast cancer, and many other cancers. Specific Aim 1. To establish Her2+/uPA+ human breast cancer cell lines for evaluation of enhanced aggressiveness. We will establish Her2+/uPA+ human breast cancer cell lines by over-expressing uPA/uPAR in the Her2-amplified SK-BR-3 and BT-474 cell lines or over-expressing Her2 in the uPA+ but Her2-negative (unamplified) MDA-MB-231 cell line; and perform in vitro evaluations of tumor aggressiveness in proliferation, migration, invasion, and anchorage-independent growth. Specific Aim 2. To treat Her2+/uPA+ human breast cancer cell lines with Herceptin, lapatinib, and WX-UK1 for evaluation of effectiveness of targeting Her2 and uPA together. With our engineered Her2+/uPA+ model cell lines, the following clinically relevant questions will be addressed: 1). whether Her2+/uPA+ breast cancers present de novo drug resistance to Herceptin or even lapatinib and whether uPA inhibition with a selective uPA inhibitor WX-UK1 overcomes the resistance; 2) whether Her2+/uPA+ breast cancers acquire resistance to anti- Her2 therapies more aggressively and whether uPA inhibition with WX-UK1 delays the acquisition of resistance. Specific Aim 3. To determine the specific actions of matriptase, prostasin, and uPA on Her2 ECD. We will use the FT-293 cell line in co-transfection experiments to determine if uPA is a Her2 ECD sheddase and if plasmin plays a role in Her2 ECD shedding; to purify protease-cleaved Her2 for mapping the cleavage sites; and to determine if the protease-cleaved Her2 is responsive to Herceptin-induced turnover. We will use the SK-BR-3 cell line to determine if the Her2 ECD shedding associated with uPA induction in breast cancer cells also involves or requires matriptase and prostasin by using specific inhibitors. PUBLIC HEALTH RELEVANCE: Resistance to chemotherapy drugs targeting Her2/neu/ErbB2 limits the success of these drugs on select groups of breast cancer patients and could render patients with acquired resistance untreatable. Proteolytic shedding of the Her2 extracellular domain/ectodomain (ECD) by proteases is a mechanism of this resistance. Our preliminary studies have identified new candidate proteases involved in Her2 ECD shedding and the proposed research will reveal if specific protease inhibitors should be considered for combination therapy to reduce or prevent the resistance to the anti-Her2 drugs.
期刊论文(1)
专著(0)
科研奖励(0)
会议论文
DOI: 10.1186/s12885-015-2039-6
发表时间: 2015-12-29
期刊: BMC cancer
影响因子: 3.8
作者: [Chai AC, Robinson AL, Chai KX, Chen LM]
通讯作者: Chen LM
Fall SBUR Meeting: Membrane Biology in Basic Urology
  • 批准号:
    7000757
  • 项目类别:
  • 资助金额:
    $0.8万
  • 财政年份:
    2005
  • 负责人:
    KARL X CHAI
  • 依托单位:
海外基金